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Abstract
ING-1(heMAb), a Human EngineeredTM monoclonal anti-
body to epithelial cell adhesion molecule (Ep-CAM),
was evaluated for its in vitro and in vivo activity. The
dissociation constant of ING-1(heMAb) for binding to
Ep-CAM on HT-29 human colon tumor cells was 2 to 5
nM, similar to chimeric ING-1. In antibody-dependent
cellular cytotoxicity and complement-dependent cyto-
toxicity assays, ING-1(heMAb) caused a concentra-
tion-dependent lysis of BT-20 breast, MCF-7 breast,
HT-29 colon, and CACO-2 colon tumor cells, with
maximum cytolysis at approximately 1 Mg/ml. After an
intravenous injection in rats, plasma ING-1(heMAb)
levels declined with an alpha half - life of 8 to 11 hours,
and a beta half - life of 20 days, typical of an IgG in a
species without the target for ING-1. In nude mice with
human HT-29 colon tumors, plasma ING-1(heMAb)
levels declined more rapidly than in non–tumor-bear-
ing mice, suggesting an enhanced clearance via the
tumor -associated human Ep-CAM. In nude mice,
intravenous treatments with ING-1(heMAb) twice a
week for 3 weeks significantly suppressed the growth
of human HT-29 colon and PC-3 prostate tumors in a
dose-dependent manner, with 1.0 mg/kg providing the
greatest benefit. These results indicate that Human
EngineeredTM ING-1(heMAb) is a high-affinity antibody
with potent in vitro activity that targets and suppresses
the growth of human tumors in vivo.
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Introduction
Monoclonal antibodies that target tumor-associated antigens
have been developed for the imaging and treatment of
human neoplasias. Because many of these antibodies are of
murine origin, a number of difficulties, including a strong
human anti–mouse antibody response and rapid clearance
in patients, have limited their therapeutic potentials [1,2 ].
These problems are overcome or reduced by using chimeric
antibodies that retain the specificity of the mouse variable
region and add the effector function of the human constant
region [3,4 ]. However, some studies indicate that chimeric
antibodies may remain immunogenic [5,6]. More recently,
murine-derived antibodies have been humanized to further
reduce these complications [7], or fully human antibodies
have been produced [8,9 ]. A number of techniques have
been utilized to humanize murine variable regions, com-
monly by grafting murine complementarity -determining
region (CDR) loops onto human framework regions [10].
One tumor-associated antigen that is often targeted by
chimeric and humanized antibodies is epithelial cell adhesion
molecule (Ep-CAM), also known as the 17-1A antigen [11],
KSA [12], EGP [13], EGP40 [14], and GA733-2 [15]. Ep-
CAM is a 40-kDa glycoprotein expressed on the basolateral
surface of many, but not all, human epithelial cells and most
human adenocarcinomas [16]. Murine antibodies to Ep-
CAM were originally described by Herlyn et al. [11 ] in 1979
and chimeric versions of anti–Ep-CAM antibodies were
subsequently developed [17]. Early chimeric antibodies
inhibited tumor growth in animal models, most likely via
antibody-dependent cellular cytotoxicity (ADCC) [18–20].
Subsequently developed high-affinity antibodies have even
greater in vivo activity, perhaps due to enhanced ADCC [21–
24]. The murine and chimeric versions of 17-1A have been
studied in patients with adenocarcinomas [5,25]. In addition,
a humanized version of 323/A3 has received initial clinical
evaluation [26]. These studies have established safe doses
for these antibodies and have suggested benefits in some
patients [25].
In 1990, Liao et al. [27] described a high-affinity chi-
meric monoclonal antibody to Ep-CAM, called ING-1, that
was derived from the murine antibody B38.1 [28], also
described as BA-Br-1 or Br-1 [29]. Chimeric ING-1
demonstrated potent ADCC and complement-dependent
cytotoxicity (CDC) against a variety of tumor cell lines
in vitro [29]. The variable region of ING-1 has now been
modified to further reduce the potential for immunogenicity in
humans using the Human EngineeringTM technology devel-
oped by Studnicka et al. [30]. This technology is an alternate
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approach to humanization of murine antibodies that takes
advantage of the conserved nature of the variable region
structure. By this approach, each amino acid within the
variable regions is analyzed and classified based on the
benefit of achieving more human- like sequences compared
with the risk of adversely affecting binding. Low-risk
changes from murine to corresponding human residues
represent changes made to surface- located amino acids not
directly involved in binding or variable region structure.
Moderate risk changes may further reduce immunogenicity
but may potentially impact binding. High-risk changes are
those that either directly impact binding or affect the proper
folding or association of the variable regions. The Human
EngineeredTM version of ING-1 that has resulted from this
approach, ING-1(heMAb), has completed preclinical and
initial clinical evaluations. ING-1(heMAb) is thus the first
antibody developed with this Human EngineeringTM technol-
ogy to be tested in patients. The clinical results available
describe the safety and immunogenicity of ING-1(heMAb)
[31,32]. No antibody response to the administration of ING-
1(heMAb) was detectable in 17 of 19 patients and only
minimal responses were detected in two patients. The
minimal immunogenicity of ING-1(heMAb) in patients
represents the initial validation of the Human Engineering
technology. However, in order for the Human EngineeringTM
approach to be truly useful, it is necessary to provide
evidence that antibodies generated from this approach
demonstrate biological activity, in addition to low immuno-
genicity. Thus, we describe here the in vitro activity, in vivo
efficacy, and pharmacokinetics of ING-1(heMAb), hereafter
referred to as ING-1.
Materials and Methods
Materials
The Human EngineeredTM ING-1 variable region was
derived from the murine B38.1 antibody by the method of
Studnicka et al. [30]. Briefly, DNA encoding 13 surface-
exposed amino acids in the murine heavy chain variable
region, and 6 in the light chain variable region were modified
to encode residues derived from human consensus se-
quences. These 19 residues were selected after all variable
region residues had been assigned a risk value ( low,
moderate, or high) as described [30]. These amino acids
were then modified to residues found in human light and
heavy chains at positions that had low risk for interfering with
either antigen binding or protein folding. ING-1 was pro-
duced from Chinese hamster ovary (CHO) cells containing
synthetic heavy and light chain genes encoding the modified
variable regions linked to human IgG1 and kappa constant
region cDNA, respectively. ING-1 was purified and then
formulated in 20 mM sodium phosphate, 0.15 M sodium
chloride, and 0.005% polysorbate 80. Cell culture media,
DME/F12, RPMI 1640, and trypsin–EDTA were obtained
from Life Technologies (Rockville, MD). Soluble Ep-CAM
was produced by CHO-K1 cells transfected with cDNA
encoding the extracellular region of Ep-CAM.
Binding Studies
In preparation for binding studies, HT-29 cells were
grown to confluency in 96-well plates. 125I - labeled ING-1
(0.1 nM) was mixed with unlabeled chimeric or Human
EngineeredTM ING-1 that was two- fold serially diluted from 1
M to 0.24 nM in 100 l of McCoy’s 5A medium sup-
plemented with 1% BSA and 10 mM HEPES (MCM buffer ).
Samples were incubated at 2 to 88C for 5 hours and then
washed three times with ice-cold MCM buffer. Bound
radioactivity in the wells was removed by adding 100 M
NaOH and counted in a LKB gamma counter. The results are
depicted as the mean of three replicate samples.
ADCC and CDC Lysis Assays
Target cells for lysis assays were cultured in DME/F12
supplemented with 10% fetal bovine serum (Hyclone,
Logan, UT). For labeling, cells were harvested with
trypsin–EDTA, resuspended in RPMI 1640 at 5106 ml1
(1–2 ml), and incubated with 100 Ci /ml 51Cr (NEN,
Boston, MA) for 45 to 60 minutes at 378C. Cells were
washed twice with RPMI 1640 and resuspended in the
appropriate medium before use.
ADCC assays were performed with peripheral blood
mononuclear cells (PBMCs) prepared from blood obtained
from healthy volunteers using acid citrate dextrose as an
anticoagulant. Sources included blood collected in Vacu-
tainer collection tubes (Becton Dickinson, Franklin Lakes,
NJ), buffy coat cells obtained from the blood bank (American
Red Cross Blood Services, Oakland, CA), and lymphaphe-
resis cells (HemaCare, Sherman Oaks, CA). PBMCs were
isolated on a Ficoll -Paque (Amersham Pharmacia Biotech,
Uppsala, Sweden) step gradient and suspended in RPMI
1640 supplemented with 10% normal human AB serum
(ABS; Sigma, St. Louis, MO). PBMCs (8105) were mixed
Figure 1. Competition binding assay. HT -29 colon tumor cells ( 210 5 cells /
well ) were incubated at 48C for 5 hours in the presence of 0.1 nM 125I - labeled
chimeric ING -1 and increasing concentrations of unlabeled ING -1 or
chimeric ING-1. The cells were then washed and counted.
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with labeled target cells (104) and varying concentrations
of ING-1, diluted in RPMI 1640 plus 10% ABS in round-
bottomed 96-well assay plates. The plates were centrifuged
for 1 minute at 250g then incubated at 378C. After 4 hours,
the plates were centrifuged for 5 minutes at 550g and
the supernatant medium was collected with a Skatron
harvestor.
CDC assays were performed with pooled human serum
collected from four healthy volunteers. Labeled target cells
were suspended in RPMI 1640 at 4105 cells /ml. Target
cells (2104) were mixed with serum and varying concen-
trations of ING-1, diluted in RPMI 1640 in round-bottomed
96-well microtiter plates. Assay plates were incubated at
378C for 3 hours, centrifuged at 550g for 5 minutes,
and the supernatant liquid was collected with a Skantron
harvestor.
Percent lysis was calculated by the equation:
% Lysis ¼ Experimental CPMSpontaneous CPM
Maximum CPMSpontaneous CPM
where Spontaneous CPM was determined from wells
containing no ING-1 and Maximum CPM was determined
from wells where target cells were lysed with 1 M HCl.
Pharmacokinetic Studies
Male CD rats (Charles River, Hollister, CA) weighing
280 to 320 g, or male athymic nude mice (NCR nu/nu;
Simonsen Laboratories, Gilroy, CA) weighing 20 to 30 g
were housed in conventional cages. The animals received
standard laboratory chow and water ad libitum in an
environmentally controlled animal room with 12-hour light–
dark cycles.
Five male rats received 50 mg/kg ING-1 (50 mg/ml),
and another five male rats received 0.5 mg/kg of ING-1
(0.5 mg/ml) via the tail vein. Blood was collected on days 0
to 91 via the retro-orbital sinus under methoxyflurane anes-
thesia. Six male rats received 5 mg/kg ING-1 (5 mg/ml)
subcutaneously at a single location. Blood samples were
collected from days 0 to 196 after dose injection. In all rat
experiments, approximately 200 l of blood was collected at
each time point into microcentrifuge tubes containing sodium
citrate. Plasma was extracted and stored at 708C until
assayed.
Ten male nude mice received 5 mg/kg ING-1 (0.5 mg/
ml) via a tail vein. In order to minimize volume depletion,
blood (100 l ) was collected from five mice after dose
injection, and at 6 hours, 3, 14, 28, 42, and 84 days later.
Blood was obtained from another five mice after dose
Figure 2. ADCC activity of ING-1 against human BT -20 breast (A ), MCF -7 breast (B ), HT -29 colon (C ) and CACO-2 colon (D ) tumor cells. Increasing
concentrations of ING-1 were added to wells containing human blood mononuclear cells and 51Cr - labeled human tumor cells in an 80:1 ratio. After incubation for
four hours at 37 8C, cell lysis was determined by counting 51Cr released into the medium. Data are from four human donors. Each symbol represents a single donor.
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injection, and then 1, 7, 21, 35, 56, and 112 days later. Ten
male nude mice with HT-29 tumors received 5 mg/kg ING-1
(0.5 mg/ml) via the tail vain. Blood collection was staggered
among the mice as before.
Measurement of ING-1 in Plasma
ING-1 was measured in rat plasma by enzyme- linked
immunosorbent assay (ELISA). Microtiter plates were
coated with the capture reagent, soluble Ep-CAM (XOMA,
Berkeley, CA), diluted in 0.25 g/ml phosphate buffered
saline (PBS). The detection system consisted of alkaline
phosphatase–conjugated goat anti–human IgG antibody
(Zymed Laboratories, South San Francisco, CA) with p -
nitrophenylphosphate as substrate. Color development was
allowed to proceed for 1 hour at room temperature and then
terminated with 100 l of 1 N NaOH. The absorbance at 405
nm was determined for all wells using a Vmax Plate Reader
(Molecular Devices, Menlo Park, CA). A standard curve was
generated and samples were quantified by interpolation from
the standard curve. Plasma standards were prepared by
adding known amounts of ING-1 to plasma. These stand-
ards were used to calculate the proportion of ING-1
recovered by the assay in plasma. A linear regression of
ING-1 concentration measured by ELISA versus added
ING-1 concentration was performed, and the calculated
slope was used as the fractional recovery. The plasma
concentrations of ING-1 in the samples were then corrected
for the recovery.
Measurement of Antibodies to ING-1
Antibodies to ING-1 in the rat were assayed by ELISA.
Microtiter plates were coated with ING-1 to which rat plasma
samples were added. The signaling system consisted of
biotin-conjugated ING-1 to which was added alkaline phos-
phatase–conjugated streptavidin (Zymed) as the enzyme
for the substrate p -nitrophenylphosphate. Standards of
different concentrations of goat anti–human IgG (Sigma)
were assayed to convert the absorbance measurements of
rat samples into goat anti–human IgG microgram-per-
milliliter equivalents.
Pharmacokinetic Analysis
Data were entered on an Alpha 3000, model 600
computer (Compaq, Maynard, TX), and analyzed using a
validated software system developed at XOMA. Data of
individual animals were fitted by nonlinear least squares
analysis using the pharmacokinetic biexponential disposition
function to describe the change in the concentration of ING-
1 with time, with the inverse of the square of the model
concentration as the weighting. The curve fits yielded four
primary pharmacokinetic parameters: volume of distribution
of the central compartment, the alpha half - life, the beta half -
life, and the coefficient to the beta half - life. Secondary phar-
macokinetic parameters were calculated from the primary
parameters in accordance with Gibaldi and Perrier [33].
Mouse Xenograft Models
Male athymic nude mice (NCR nu/nu; Simonsen Labo-
ratories), 20 to 25 g, were maintained in a pathogen- free
facility. The mice were kept in filter - topped cages and
handled under a laminar flow hood. Each mouse received a
subcutaneous injection of 3106 HT-29 colon tumor cells or
5106 PC-3 prostate cells in a flank region. After 24 hours,
groups of 10 mice received ING-1 at 0.1, 0.3, or 1.0 mg/kg.
Control mice received 1 mg/kg human IgG1. Dosing was
continued for 3 weeks, at two doses per week. After tumors
could be palpated, length and width measurements were
obtained twice a week with microcalipers. Tumor volumes
were calculated as LW2 /2. Differences in mean tumor
volumes between groups were analyzed by a one-way
analysis of variance with repeated measures. Post -hoc
analysis was performed with Tukey’s honest significant dif-
ference test.
Results
ING-1 Binding to Ep-CAM
The ability of increasing concentrations of unlabeled ING-
1 to compete with a fixed concentration of 125I - labeled
Figure 3. CDC activity of ING-1. Increasing concentrations of ING-1 were
added to wells containing 210 4 51Cr - labeled HT -29 colon tumor cells and
different amounts of human serum. After 24 hours of incubation at 37 8C, 51Cr
was counted.
Figure 4. Plasma clearance of ING-1 in rats. ING-1 was administered
intravenously (0.5 and 50 mg /kg ) or subcutaneously (5 mg / kg ), and plasma
levels were measured by ELISA.
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chimeric ING-1 for binding to Ep-CAM on HT-29 human
colon tumor cells was evaluated. Both ING-1 and chimeric
ING-1 competed similarly with radiolabeled chimeric ING-1
for binding to Ep-CAM (Figure 1). Scatchard analysis of the
data from four independent experiments was used to
calculate an antibody dissociation constant (Kd) of 2 to 5
nM for ING-1. The number of antigen sites on HT-29 cells
was estimated to be 1.5106 per cell. The affinity of ING-1
for Ep-CAM on HT-29 colon tumor cells appeared to be
indistinguishable from that previously described for the
chimeric ING-1 antibody [29].
ADCC and CDC Assays
PBMCs from four separate donors and 51Cr- labeled
human tumor target cells (80:1 ratio) were incubated with
increasing concentrations of ING-1. ING-1 caused a
concentration-dependent lysis of BT-20 breast (Figure
2A ), MCF-7 breast (Figure 2B ), HT-29 colon (Figure 2C ),
and CACO-2 colon (Figure 2D ) tumor cells. Although
maximal killing occurred at approximately 1 g/ml, signifi-
cant cytotoxicity was observed at much lower concentra-
tions. In other experiments, ING-1 caused similar levels of
lysis of non small cell lung (NCI-H1568), prostate (PC-3),
and pancreatic (HPAF- II ) tumor cells (data not shown).
In order to determine if ING-1 mediates CDC, 51Cr-
labeled HT-29 colon tumors cells were incubated with
different amounts of serum. The ability of increasing concen-
trations of ING-1 to lyse the tumor cells was measured as a
release of 51Cr into the supernatant. ING-1 caused a dose-
dependent lysis of the tumors cells with maximal killing
occurring at approximately 1 g/ml (Figure 3).
Pharmacokinetics in Rats
The decline in plasma concentration with time of in-
travenously administered ING-1 in an antigen-negative
species ( rats) could be described by a biexponential phar-
macokinetic disposition function (Figure 4 and Table 1). The
alpha-phase half - lives were approximately 6 and 13 hours
for 0.5 and 50 mg/kg, respectively, whereas the beta-phase
half - lives were approximately 18 and 17 days, respectively
(Table 1). The clearance was approximately 4.5 ml/kg
per day at the two doses. Thus, the clearance of ING-1
was dose- independent over the dose range studied. The
plasma concentration–time profile did not reveal a change
of kinetics at 10 to 14 days or later, suggesting that there
was no host antibody production that altered ING-1
clearance.
After subcutaneous administration of 5.0 mg/kg ING-1,
plasma concentrations increased to a peak concentration of
21.5±0.7 g/ml by 4.94±0.41 days. Thereafter, the plasma
ING-1 levels declined with a half - life of 16.7±0.8 days,
similar to the beta half - life observed after intravenous
administration. The bioavailability of subcutaneously admin-
istered ING-1 relative to intravenously administered ING-1
was calculated to be 57±4%. In one of the rats, the ING-1
plasma level declined rapidly after day 7, and was below
detection by day 14. As a result of this observation, plasma
from all rats was assayed for anti–human antibodies.
Antibodies were detected in the plasma of the one rat with
altered clearance 21 and 70 days after injection, but not in
Table 1. Pharmacokinetic Parameters in Rats.
Dosing (mg / kg ) Vc (ml / kg ) Vss (ml / kg ) Cl (ml / kg per day ) MRT (hours ) a ( hours ) b ( days )
0.5, i.v. 49.2±2.9 108±7 4.43±0.33 24.5±1.5 12.9±6.2 17.7±0.9
50, i.v. 75.2±8.1 114±9 4.56±0.37 25.0±0.8 5.85±0.90 17.4±0.6
Dosing (mg / kg ) Tmax (hours ) Cmax (g /ml ) Cl (ml / kg per day ) MRT (hours ) a ( hours ) b ( days )
5.0, s.c. 4.94±0.41 21.5±0.7 7.95±0.43 25.9±1.2 29.4±3.5 16.7±0.8
Vc, volume of distribution of the central compartment; Vss, steady state volume of distribution; Cl, clearance; MRT, mean residence time; a, alpha - phase half - life;
b, beta - phase half - life; Fb, fraction of clearance attributable to the beta -phase half - life; Tmax, time to maximal concentration; Cmax, maximal concentration.
Figure 5. Plasma clearance of ING-1 in nude mice. Nude mice with or without
human HT -29 colon tumors were administered 5 mg /kg ING-1, i.v., and
plasma levels were measured by ELISA.
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the predose sample. No detectable levels of anti–human
antibody were measured in the other rats.
Pharmacokinetics in Nude Mice
Thirteen male nude mice with HT-29 human colon tumors
that averaged 195 mm3 received an intravenous bolus of 5
mg/kg ING-1. By 49 days postdose, the average tumor
volume was 2200 mm3. An additional 13 mice that did not
bear tumors received an intravenous bolus of 5 mg/kg
ING-1. In mice without tumors, the decline in plasma con-
centration of ING-1 with time could be described by a biex-
ponential pharmacokinetic disposition function (Figure 5).
The average alpha-phase half - life was 2.8±2.4 hours and
the beta-phase half - life was 10.1±0.5 days. The central
compartment volume of distribution was 53±17 ml /kg,
similar to plasma volume, and the clearance was 9.7±1.1
ml /kg per day. In tumor-bearing mice, the decline in plasma
concentration of ING-1 with time could be described by a
biexponential pharmacokinetic disposition function for the
first 14 days after dosing. The average alpha-phase half - life
was 1.9±0.7 hours and the beta-phase half - life was
5.7±0.4 days. The central compartment volume of distribu-
tion was 56±5 ml/kg and the clearance, based on the first 14
days, was 15.1±0.7 ml /kg per day. After 14 days, the
plasma concentration of ING-1 declined more rapidly to near
detection levels (5 ng/ml) on day 49, with an effective half -
life of about 2 days.
Efficacy in Mouse Xenograft Models
Figure 6 illustrates the effect of ING-1 on growth of HT-
29 colon tumors in nude mice. ING-1 treatment two times
per week, intravenously for 3 weeks, resulted in a dose-
dependent reduction in tumor size relative to control. A dose
of 1 mg/kg ING-1 resulted in a 64% reduction in tumor size
at the end of the experiment. Figure 7 shows that similar
results were obtained in nude mice with PC-3 prostate
xenografts. ING-1 treatment, at 1 mg/kg administered twice
a week for 3 weeks, resulted in a 71% reduction in tumor
volume.
Discussion
This study provides the first description of the in vitro and in
vivo activity of the Human EngineeredTM monoclonal anti-
body ING-1 that targets the human cell adhesion molecule
Ep-CAM. The data indicate that our Human Engineering
technology did not alter the functional characteristics of the
antibody relative to chimeric ING-1 as indicated by the
retention of high binding to Ep-CAM and potent ADCC
and CDC activity. Here we also provide the first detailed
description of the in vivo efficacy and pharmacokinetics of
ING-1.
The binding data illustrated in Figure 1 demonstrate
that ING-1 is in the high-affinity class of anti–Ep-CAM
antibodies, with a dissociation constant of 2 to 5 nM — a
level of affinity similar to chimeric ING-1. In addition, the
Kd of ING-1 is similar to that reported for other high-
affinity chimeric or humanized anti–Ep-CAM antibodies,
including 323/A3 (2 nM) [34] and USB-54 (5 nM) [8]. It
has been suggested that high affinity (Kd>10
8) increases
the likelihood of antibody uptake into a tumor [35,36],
although it has been argued by others that low-affinity
antibodies may penetrate deeper into a tumor nodule [34].
Indeed, autoradiographic studies suggest that 323/A3 may
preferentially localize near blood vessels, whereas low-
affinity 17-1A exhibits a homogenous distribution within
tumors [21,34]. Regardless, several other factors, including
antigen distribution and density as well as tumor perfusion,
affect the therapeutic benefit of these antibodies in exper-
imental studies [37].
One of the factors believed to be especially important for
benefits with anti–Ep-CAM antibodies is an interaction with
host effector cells. A number of studies indicate that high-
affinity anti–Ep-CAM antibodies may exhibit greater activity
in ADCC assays compared to the low-affinity murine 17-1A,
and that these antibodies demonstrate CDC activity as well
[7,8,21,24]. Our results indicate that ING-1 also exhibits
potent ADCC and CDC activity that is not apparently different
from that demonstrated previously by chimeric ING-1 [29].
The results illustrated in Figure 2 demonstrate ADCC ac-
tivity against breast and colon tumor cells, with maximal
lysis approaching 100% against one cell line. Furthermore,
Figure 7. PC-3 tumor growth in nude mice treated with ING-1. Groups of 10
mice received ING-1 or human IgG 24 hours after tumor cell implantation.
Data are mean±SEM *P< .05 vs IgG; **P< .01.
Figure 6. HT-29 colon tumor growth in nudemice treated with ING-1. Groups
of 10 mice received ING -1 or human IgG 24 hours after tumor cell
implantation. Data are mean±SEM. *P< .05 vs IgG; **P< .01.
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although maximal killing was observed at approximately 1
g/ml, as much as 50% lysis was evident at concentrations
as low as 10 ng/ml. Although CDC activity was demon-
strated, the activity observed was modest. This result is
similar to results with other anti–Ep-CAM antibodies [8]
and is probably due to the presence of complement
regulatory proteins on tumor cells. In addition, the source
of complement was human serum, which may have varying
degrees of complement activity in vitro.
In vivo benefit with anti–Ep-CAM antibodies requires
that the drug circulate at sufficiently high levels to interact
with tumor cells and engage effector cells to evoke cyto-
toxic responses. Our pharmacokinetic results clearly dem-
onstrate that ING-1 reaches adequate levels (>1 g) for
sufficient time to be evaluated as a potential therapeutic
agent. The results also demonstrate that the clearance pro-
file of ING-1 in nude mice without tumors, and in rats, is
dose- independent and is similar to that of a typical native
IgG1 without a specific host target site. The terminal half -
lives of 10 days for ING-1 in nude mice without tumors and
20 days in rats were similar to that previously reported for
native IgG1 [38,39].
In contrast to the above experiments, the pharmacoki-
netics of ING-1 in tumor-bearing mice suggests that the
presence of antigen-positive tumors results in more rapid
clearance than was observed in tumor-negative mice.
Figure 5 illustrates that, after 3 days, the increased clearance
resulted in a nearly two- fold faster beta-phase half - life
compared to mice without human tumors. Furthermore,
after 21 days, there was an ever- increasing proportional
decrease in clearance rate. Such a concentration–time
profile is characteristic of a drug that is cleared by a slow,
nonsaturable elimination mechanism at high concentrations,
and a faster saturable elimination mechanism at lower con-
centrations, presumably represented by human Ep-CAM
in the tumors. The concentration–time profile of ING-1 in
tumor-bearing mice is also characteristic of proteins that
bind to specific host target sites of low capacity and high
affinity [40–43].
As the presence of a human target site is the best
explanation for the altered clearance of ING-1 in tumor-
bearing mice, our pharmacokinetics suggests a direct
interaction of ING-1 with human tumor cells in nude mice.
Tumor penetration, as well as the potent cytotoxic activity of
ING-1 in vitro, are the characteristics required for successful
in vivo treatment of experimental tumors. Our efficacy
studies clearly demonstrate that ING-1 suppresses the
growth of HT-29 colon and PC-3 prostate tumors in nude
mice. The effect we observed in this study was dose-
dependent with 1 mg/kg, i.v., twice a week providing sig-
nificant efficacy at most time points and 0.3 mg/kg was also
effective by the end of the experiments (Figures 6 and 7).
The nude mouse, while almost devoid of T lymphocytes, is
well endowed with other effector cells [44]. Thus, the
mechanism by which ING-1 inhibited tumor growth in these
experiments is most likely ADCC. In a series of studies by
Herlyn et al., evidence was presented that the in vivo activity
of murine 17-1A resulted from ADCC that is mediated by
macrophages [17,45–47]. Since then, others have sug-
gested that anti–Ep-CAM antibodies interact with natural
killer cells and neutrophils as well as macrophages in vivo
[19,48,49]. A prominent role for CDC in the in vivo activity of
these antibodies is doubtful because complement depletion
does not alter the effectiveness of 17-1A [18] and tumor
cells are well endowed with membrane-bound complement
inhibitory proteins [50,51].
Whereas these results demonstrate the in vitro and in vivo
activity of ING-1, they also provide the first description of
the biological activity of an anti–Ep-CAM antibody gen-
erated by the Human Engineering technology of Studnicka et
al. [30]. These data thus support the use of this technology
for generating antibodies with desirable characteristics for
human use. An important advantage of the Human Engineer-
ing method over other humanization technologies is its re-
lative simplicity. Despite the simplified nature of the
technology, it generates antibodies with variable region
sequences that are more human- like than murine variable
region sequences and that retain the binding activity of the
murine version. For example, this method is more direct than
CDR grafting techniques that require replacement of the
entire murine framework with a human framework followed
by a series of ‘‘dehumanizing’’ steps to recover binding
activity [10].
In summary, these results demonstrate that Human
Engineering of ING-1 results in a high-affinity antibody that
demonstrates potent in vitro and in vivo efficacy. As Ep-CAM
is highly expressed in human adenocarcinomas, targeting
this tumor antigen with ING-1 may provide a therapeutic tool
that is useful for the treatment of patients with adenocarci-
nomas and that evokes minimal immunogenicity. This
suggestion is supported by preliminary clinical studies
demonstrating the safety and low immunogenicity of ING-1
in cancer patients [31,32].
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